XOMA is a biotech royalty aggregator. Co. has a pipeline of monoclonal antibodies and technologies available to license to pharmaceutical and biotechnology companies, including: PTH1R program, which is an anti-parathyroid receptor pipeline that includes functional antibody antagonists targeting PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism; XMetA, which is an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients, reducing the advancement to a number of insulin injections needed to control their blood glucose levels; and X213, which is an allosteric inhibitor of prolactin action. The XOMA stock yearly return is shown above.
The yearly return on the XOMA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the XOMA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|